Taxotere gets fast track status for head and neck cancer indication

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 8
Volume 16
Issue 8

Taxotere gets fast track status for head and neck cancer indication

BRIDGEWATER, New Jersey—Sanofi-aventis has received priority review from the FDA for its supplemental New Drug Application for Taxotere (docetaxel) in combination with cisplatin and fluorouracil for induction (neoadjuvant) therapy of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) prior to chemoradiotherapy and surgery. The combination is currently approved for induction therapy of inoperable advanced SCCHN. The submission is based on the TAX 324 phase III study showing significantly improved overall survival in patients treated with the Taxotere combination vs cisplatin/fluorouracil alone.

Articles in this issue
Avoiding copay shock
Induction chemo increases survival in unresectable NSCLC
Superselective chemo strategies for HCC
'Value meal dosing' of lapatinib is proposed
AMA approves CPT code for Axxent electronic brachytherapy
Zevalin/R after CHOP-R doubles CRs in follicular NHL
Active surveillance with delayed treatment appears to be a safe option for younger men with low-risk prostate cancer
RT plus local paclitaxel gel promising in esophageal ca
GeneSearch BLN Assay gets FDA approval for node assessment during surgery
TH vs TCH in metastatic breast cancer: 'Take your pick'
Sunitinib prolongs PFS in RCC: update
Diagnostic Dilemma: GI Disease
ACS studies link patients' insurance status to cancer outcomes
Novel MAGE-A3 immunotherapeutic promising as adjuvant therapy of early-stage non-small-cell lung ca
US consumers are shielded from the cost of healthcare
Recent Videos
Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.
Overall survival also appears to improve with toripalimab compared with chemotherapy among patients with metastatic or advanced nasopharyngeal carcinoma.
head and neck cancer
head and neck cancer
head and neck cancer
Related Content
Cisplatin/70 Gy IMRT Cemented as SOC for Nonsmoking p16+ Oropharyngeal Cancer

Cisplatin/70 Gy IMRT Cemented as SOC for Nonsmoking p16+ Oropharyngeal Cancer

Gina Mauro
September 30th 2024
Article

Experimental regimens did not cross the threshold to show superiority vs standard cisplatin plus 70 Gy radiation in those with HPV-associated oropharynx cancer.

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David J. Sher, MD, MPH
September 15th 2017
Podcast

In this interview we discuss new clinical guidelines from ASTRO on the use of radiotherapy in treating oropharyngeal cancer.

Phase 2 data also highlight an improvement in disease control rate with setanaxib/pembrolizumab in squamous cell carcinoma of the head and neck.

Setanaxib/Pembrolizumab Improves Survival in Head and Neck Cancer

Russ Conroy
May 8th 2024
Article

Phase 2 data also highlight an improvement in disease control rate with setanaxib/pembrolizumab in squamous cell carcinoma of the head and neck.

Head and neck cancer

Early Intervention, Regular Assessment Can Grasp Symptom Course for Head and Neck Cancer Therapy

Darlene Dobkowski, MA
April 28th 2024
Article

Nurses must increase the frequency of their assessments for early intervention of patients who undergo treatment for their head and neck cancer, in an effort to truly individualized care.

FDA Gives Fast Track Designation to LYT-200 in Advanced Head and Neck Cancers

FDA Gives Fast Track Designation to LYT-200 in Advanced Head and Neck Cancers

Ariana Pelosci
April 12th 2024
Article

LYT-200 is currently being investigated for those with solid tumors and hematologic malignancies.

Prognostic Factors Linked With Poor Locoregional Control in Tongue Cancer | Image Credit: © freshidea - stock.adobe.com.

Prognostic Factors Linked With Poor Locoregional Control in Tongue Cancer

Gina Mauro
March 5th 2024
Article

Patients with factors such as lymphovascular space invasion or positive glossectomy specimen margins may be considered for adjuvant radiotherapy to optimize disease control of tongue squamous cell carcinoma.